{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:45:47Z","timestamp":1771461947687,"version":"3.50.1"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"37","license":[{"start":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T00:00:00Z","timestamp":1649376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,7]]},"DOI":"10.1093\/eurheartj\/ehac128","type":"journal-article","created":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T20:10:47Z","timestamp":1646165447000},"page":"3575-3577","source":"Crossref","is-referenced-by-count":5,"title":["Galectin-3 inhibitors as novel antithrombotic drugs with almost no bleeding risk: wishful thinking or a realistic vision?"],"prefix":"10.1093","volume":"43","author":[{"given":"Kai","family":"Jakobs","sequence":"first","affiliation":[{"name":"Department of Cardiology, Campus Benjamin Franklin Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin , Berlin , Germany"},{"name":"DZHK (German Centre for Cardiovascular Research), Partner Site Berlin , Berlin , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1544-7644","authenticated-orcid":false,"given":"Ursula","family":"Rauch","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Campus Benjamin Franklin Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin , Berlin , Germany"},{"name":"DZHK (German Centre for Cardiovascular Research), Partner Site Berlin , Berlin , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,4,8]]},"reference":[{"key":"2022102708181498100_ehac128-B1","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3390\/ijms19020379","article-title":"Galectin-3: one molecule for an alphabet of diseases, from A to Z","volume":"19","author":"Sciacchitano","year":"2018","journal-title":"Int J Mol Sci"},{"key":"2022102708181498100_ehac128-B2","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/s41598-019-38497-8","article-title":"Extracellular and intracellular small-molecule galectin-3 inhibitors","volume":"9","author":"Stegmayr","year":"2019","journal-title":"Sci Rep"},{"key":"2022102708181498100_ehac128-B3","doi-asserted-by":"crossref","first-page":"593","DOI":"10.7150\/thno.22196","article-title":"Galectin-3 activation and inhibition in heart failure and cardiovascular disease: an update","volume":"8","author":"Suthahar","year":"2018","journal-title":"Theranostics"},{"key":"2022102708181498100_ehac128-B4","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1161\/HYPERTENSIONAHA.118.11874","article-title":"CT-1 (Cardiotrophin-1)\u2013Gal-3 (Galectin-3) axis in cardiac fibrosis and inflammation","volume":"73","author":"Martinez-Martinez","year":"2019","journal-title":"Hypertension"},{"key":"2022102708181498100_ehac128-B5","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1161\/ATVBAHA.107.159160","article-title":"Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction","volume":"28","author":"Papaspyridonos","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022102708181498100_ehac128-B6","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1161\/ATVBAHA.114.304964","article-title":"Galectin-3 predicts long-term cardiovascular death in high-risk patients with coronary artery disease","volume":"35","author":"Maiolino","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022102708181498100_ehac128-B7","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2353\/ajpath.2008.070348","article-title":"Galectin-3 gene inactivation reduces atherosclerotic lesions and adventitial inflammation in ApoE-deficient mice","volume":"172","author":"Nachtigal","year":"2008","journal-title":"Am J Pathol"},{"key":"2022102708181498100_ehac128-B8","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1093\/eurheartj\/ehac034","article-title":"Galectin 3 enhances platelet aggregation and thrombosis via Dectin-1 activation: a translational study","volume":"43","author":"Chen","year":"2022;","journal-title":"Eur Heart J"},{"key":"2022102708181498100_ehac128-B9","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.5551\/jat.12856","article-title":"Value and level of galectin-3 in acute myocardial infarction patients undergoing primary percutaneous coronary intervention","volume":"19","author":"Tsai","year":"2012","journal-title":"J Atheroscler Thromb"},{"key":"2022102708181498100_ehac128-B10","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1016\/j.jacc.2018.09.076","article-title":"Longitudinal change in galectin-3 and incident cardiovascular outcomes","volume":"72","author":"Ghorbani","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2022102708181498100_ehac128-B11","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.1002\/ehf2.13595","article-title":"Biomarkers in the management of acute heart failure: state of the art and role in COVID-19 era","volume":"8","author":"Aleksova","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2022102708181498100_ehac128-B12","first-page":"85","article-title":"Platelets and galectins","volume":"2","author":"Schattner","year":"2014","journal-title":"Ann Transl Med"},{"key":"2022102708181498100_ehac128-B13","first-page":"2002559","article-title":"Target-inhibition of Galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis","volume":"57","author":"Hirani","year":"2020","journal-title":"N Engl J Med"},{"key":"2022102708181498100_ehac128-B14","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1182\/blood-2014-04-569939","article-title":"The role of galectin-3 and galectin-3-binding protein in venous thrombosis","volume":"125","author":"DeRoo","year":"2015","journal-title":"Blood"},{"key":"2022102708181498100_ehac128-B15","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1080\/09537104.2020.1849600","article-title":"Novel antiplatelet strategies targeting GPVI, CLEC-2 and tyrosine kinases","volume":"32","author":"Harbi","year":"2021","journal-title":"Platelets"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/43\/37\/3575\/46650623\/ehac128.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/43\/37\/3575\/46650623\/ehac128.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T08:18:39Z","timestamp":1666858719000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/43\/37\/3575\/6564924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,8]]},"references-count":15,"journal-issue":{"issue":"37","published-online":{"date-parts":[[2022,4,8]]},"published-print":{"date-parts":[[2022,10,7]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehac128","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,10,7]]},"published":{"date-parts":[[2022,4,8]]}}}